ArticleJournal of bone oncology2019

An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain.

Sarah Danson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.